Apimeds Pharmaceuticals says “I love my Ducks” with new ai² Futures Lab Program collaboration with the University of Oregon’s Lundquist College of Business

Apimeds Pharmaceuticals US, Inc. (NYSE: APUS) (“Apimeds”) today announced the expansion of the Apimeds ai^² Futures Lab program through a new collaboration with the University of Oregon’s Lundquist College of Business, starting with the Winter 2026 quarter. The initiative connects student teams with real-world biopharma business development projects, reinforcing Apimeds’ commitment to fostering innovation, leadership, and discovery across the healthcare ecosystem.

ai^² Futures Lab functions as both a discovery engine for potential therapeutic assets and a training ground for tomorrow’s industry leaders. Through this collaboration, University of Oregon students will engage directly with Apimeds mentors to evaluate early-stage or shelved pharmaceutical assets, conduct market and IP analysis, and identify opportunities to advance patient care through novel business strategies.

“As a proud University of Oregon alum, I couldn’t be more excited,” said Erik Emerson, CEO of Apimeds Pharmaceuticals. “The Lundquist College of Business is an ideal partner to help expand our ai^² Futures Lab initiative. This program embodies what we value most at Apimeds—bridging human insight and scientific innovation. ai^² Futures Lab fuels our pipeline with fresh, data-driven thinking, while allowing students at the University of Oregon to build on the Oregon tradition of innovation, collaboration and, as Oregon alumni appreciate, being your favorite team’s favorite team.”

Bruce Blonigen, Edward Maletis Dean of the Lundquist College of Business, added, “We’re thrilled to bring this hands-on opportunity to our students. Collaborating with an innovative partner like Apimeds provides real-world experience that helps prepare students for careers at the intersection of science, business, and innovation. It’s a perfect reflection of the Lundquist approach—learning by doing, with purpose and impact.”

Brian Peters, SVP of Apimeds’ ai^² Division and ai^² Futures Lab program lead, noted, “This partnership deepens our mission to transform ai^² Futures Lab into a scalable development platform for Apimeds and a launchpad for young innovators. Each team is working on real assets with real potential, creating value both for the company and for the students shaping the future of healthcare.”

The University of Oregon is the third academic institution with which the ai^² Futures Lab is collaborating, following the University of Alabama and the University of San Diego. The program continues to expand as a cornerstone of Apimeds’ ai^² innovation platform, which integrates actual intelligence—the power of human insight—with AI-driven analytics to identify transformative opportunities in biotechnology.